Akoustis Technologies Inc reports results for the quarter ended in June - Earnings Summary

Aktis Oncology

06/09/2023 14:32

* Akoustis Technologies Inc  AKTS.OQ  reported a quarterly
adjusted loss of 21 cents​​ per share for the quarter ended in
June. The mean expectation of five analysts for the quarter was
for a loss of 17 cents per share.
    * Revenue rose 60.2% to $8.33 million from a year ago;
analysts
expected $8.44 million. 
    * Akoustis Technologies Inc's reported EPS for the quarter
was a
loss of 25 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Akoustis Technologies Inc shares had fallen by 48.1% this
quarter and lost 41.5% so far this year.
    * The company reported a quarterly loss of $17.77 million.
    * Wall Street's median 12-month price target for Akoustis
Technologies Inc is $6.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
September 6 at 01:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.17          -0.21          Missed
 Mar. 31 2023      -0.19          -0.20          Missed
 Dec. 31 2022      -0.25          -0.19          Beat
 Sep. 30 2022      -0.20          -0.28          Missed